Cipla chief offers generic Atripla at African prices to counter MGH study
This article was originally published in Scrip
Executive Summary
Cipla's chairman and managing director, Dr Yusuf Hamied, has rebutted the claims of a recent study led by the Massachusetts General Hospital (MGH) in the US, which suggests that replacing certain brand name antiretrovirals with generics could diminish treatment effectiveness.